Navigation Links
Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer
Date:12/11/2009

REDWOOD CITY, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company focused on the development of improved versions of protein drugs, today announced that it has extended the expiration date for its modified "Dutch Auction" tender offer to repurchase 6,557,377 shares of its common stock, which was commenced on November 13, 2009. The tender offer, which was previously scheduled to expire at 12:00 midnight, New York City time, on Friday, December 11, 2009, will be extended until 5:00 p.m., New York City time, on Wednesday, December 23, 2009. The tender offer remains subject to all previously announced terms and conditions.

As of 5:00 p.m., New York City time, on Thursday, December 10, 2009, 687,535 shares of common stock have been tendered pursuant to the offer.

IMPORTANT NOTICE: On November 13, 2009, Maxygen commenced a modified "Dutch Auction" tender offer to repurchase 6,557,377 shares of its common stock. This press release is for informational purposes only and is neither an offer to buy nor the solicitation of an offer to sell any shares of Maxygen's common stock. The tender offer is being made solely by the offer to purchase, the related letter of transmittal and other related documents that Maxygen has previously sent to its stockholders. The materials have been filed as exhibits to Maxygen's tender offer statement on Schedule TO, which was originally filed with the Securities and Exchange Commission on November 13, 2009 (as subsequently amended or supplemented to date). These tender offer materials contain important information that investors are urged to read carefully before making any decision with respect to the tender offer. Each of these documents has been or will be filed with the Securities and Exchange Commission, and investors may obtain them for free from the Securities and Exchange Commission at its website (www.sec.gov) or from Okapi Partners, the information agent for the tender offer, by directing such request to: Okapi Partners LLC, 780 Third Avenue, 30th Fl., New York, NY 10017, telephone (212) 297-0720 or toll-free (877) 285-5990.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. For more information, please visit www.maxygen.com.

SOURCE Maxygen, Inc.


'/>"/>
SOURCE Maxygen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Maxygen, Inc. Commences Dutch Auction Tender Offer to Repurchase 6,557,377 Shares of Common Stock
2. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
3. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
4. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
5. RetireSafe Announces Intention to Key Vote Senator Dorgans Drug Importation Amendment (SA 2793)
6. Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign
7. Neogen Corporation Announces 2nd Quarter Results
8. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
9. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
10. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
11. Vivakor Announces New Acquisition Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  iCAD (Nasdaq: ICAD), ... solutions and radiation therapy for the early identification ... Tomo Detection received Premarket Approval (PMA) from the ... Detection is a first-of-its-kind, concurrent-read computer aided detection ... the latest innovation available on the PowerLook® Breast ...
(Date:3/27/2017)... 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced ... M. Bisaro as Impax,s President and Chief Executive ... March 27, 2017. Mr. Bisaro will succeed J. ... and Chief Executive Officer since December of 2016. ... pharmaceutical experience, Mr. Bisaro, 56, is an accomplished global ...
(Date:3/27/2017)... March 27, 2017   Genprex, Inc. , a privately held, ... Pham , MD, the Company,s Chief Operating Officer, is scheduled to ... Sachs 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, ... York, NY ... BioCentury 24th Annual Future Leaders in Biotech Industry – ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... American ... conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a ... with the April edition of American Veterinarian™. , “We look forward ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... management program at Women’s Excellence will help patients lose weight and keep it ... The specialists at Women's Excellence will measure BMI, body fat composition, and ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... ... March 27, 2017 , ... The ... supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, ... , “Increasingly, supply chain and value analysis professionals have a ‘seat at the ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... According to ... prostate cancer, including all stages, is more than 95%. Once the cancer spreads to ... less than 30%. To find out how to avoid this latter group, tune in ...
Breaking Medicine News(10 mins):